| Name | Title | Contact Details |
|---|
Aerolase designs, manufactures and markets the LightPod family of lasers, which represent a technology breakthrough in the field of laser medicine. The result is a new generation of aesthetic and dermatology lasers, built on the proven safety and versatility of gold-standard medical laser modalities. LightPod lasers deliver the highest power for aesthetic & dermatology treatments with uniquely optimized laser pulse parameters based on clinical research. They lead the industry with an unprecedented combination of Efficacy, Safety, Versatility, and Return on Investment.
Embody, Inc. is a commercial-stage company pioneering the next generation regenerative platform for the repair of tendon and ligament injuries with novel collagen-based bio-fabrication techniques and products for the fast-growing sports medicine market. Founded in 2014, the company is developing unique biomaterials with an initial focus on orthopedic applications including Achilles, rotator cuff and knee ligament repair.
Founded in 1999, Dexcom, Inc. is transforming diabetes care and management by providing superior continuous glucose monitoring (CGM) technology to help patients and healthcare professionals better manage diabetes. Since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions that are best in class - while empowering our community to take control of diabetes.
Tunstall Healthcare is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 100,000 implanted to date.